Early immune therapy may save sight in rare eye disease
NCT ID NCT03399175
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study looks at whether starting strong anti-inflammatory drugs early can help control Vogt-Koyanagi-Harada (VKH) disease, a rare condition that causes eye inflammation and vision loss. About 40 people with newly diagnosed VKH will receive high-dose steroids and immune-suppressing medicines. Researchers will track eye health using special tests over at least one year to see if early treatment reduces damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VOGT KOYANAGI HARADA DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de Sao Paulo
RECRUITINGSão Paulo, São Paulo, 05403-000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.